Scientific References

American Cancer Society. What are the survival rates for melanoma skin cancer by stage? American Cancer Society: www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-survival-rates. Published October 29, 2013. Accessed October 29, 2013.

Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.

Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010;28:2452-9.

Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2011; 65(5): 1032-1047.

Coit DG, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma. Version 2.2013

Dhillon, et al. Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with Stage I and Stage II cutaneous melanoma. J Clin Oncol 2012;30(suppl; abstr 8543).

Gerami P, Cook RW, Russell MC, et al. Gene expression profile prediction of metastasis in thirty Stage III sentinel lymph node positive cutaneous melanoma tumors. Pigm Cell Melanoma R 2013;26(6):953.

Gerami, et al. Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma. Clin Cancer Res, 2015 21; 175.

Gerami, et al. Gene Expression Profiling for Molecular Staging of Cutaneous Melanoma in Patients Undergoing Sentinel Lymph Node Biopsy. J Am Acad Dermatol. 2015;72(5):780-785.

Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.

Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003; 238:528-35; discussion 35-7.

Lawson, D, et al. Gene expression profile of primary cutaneous melanomas to distinguish between low and high risk of metastasis.  J Clin Oncol 2013;31(suppl; abstr 9022).

Lawson D, Russell MC, Wilkinson J, et al. Development of a genetic signature that can accurately predict metastasis in Stage I and II cutaneous melanoma. Pigm Cell Melanoma R 2013;26(6):970.

Melanoma of the Skin (2010). In S.B. Edge (Ed.). American Joint Committee on Cancer (pp 325-344). New York, NY: Springer.

Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-17.

Know Your Risk

DecisionDx-Melanoma

A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation